CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Not Yet Opened 09-24 16:00:00 EDT

2.52

+0.01

+0.40%

盘后2.54

+0.02+0.79%

19:58 EDT

High2.53	Low2.43	Vol91.01K
Open2.46	D1 Closing2.51	Amplitude3.98%
Mkt Cap38.10M	Tradable Cap24.20M	Total Shares15.12M
T/O226.18K	T/O Rate0.95%	Tradable Shares9.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":2.52,"timestamp":1790280000000,"preClose":2.51,"halted":0,"volume":91008,"hourTrading":{"tag":"盘后","latestPrice":2.54,"preClose":2.52,"latestTime":"19:58 EDT","volume":735,"amount":1862.84,"timestamp":1790294290668,"change":0.02,"changeRate":0.007937,"amplitude":0.007937},"delay":0,"changeRate":0.003984063745020013,"floatShares":9604400,"shares":15119100,"eps":-3.195903,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"09-24 16:00:00 EDT","open":2.46,"high":2.53,"low":2.43,"amount":226178.19624959998,"amplitude":0.039841,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.195903,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790323200000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":2.51,"preHourTrading":{"tag":"盘前","latestPrice":2.4593,"preClose":2.51,"latestTime":"08:51 EDT","volume":2024,"amount":5126.862030400001,"timestamp":1790254289174,"change":-0.0507,"changeRate":-0.020199,"amplitude":0.037729},"postHourTrading":{"tag":"盘后","latestPrice":2.54,"preClose":2.52,"latestTime":"19:58 EDT","volume":735,"amount":1862.84,"timestamp":1790294290668,"change":0.02,"changeRate":0.007937,"amplitude":0.007937},"volumeRatio":0.573313},"requestUrl":"/m/hq/s/CRVO/tweets","defaultTab":"tweets","newsList":[{"id":"2669149183","title":"CervoMed Joins ROTH Healthcare Opportunities Conference Neuroscience Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2669149183","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669149183?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:31","pubTimestamp":1790076673,"startTime":"0","endTime":"0","summary":"CervoMed joins ROTH Healthcare Opportunities Conference neuroscience panelCervoMed management will attend the 5th Annual ROTH Healthcare Opportunities Conference in New York on Sept. 29, 2026.Executiv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL2N4dx4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BCDF","SG9999014005.SGD","SG9999014013.SGD","BK4588","LU0314104364.USD","BK4585","CRVO","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","NDAQ","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BQXX3C00.GBP","BK4139","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666516833","title":"CervoMed highlights late-breaking neflamapimod Phase 2a data","url":"https://stock-news.laohu8.com/highlight/detail?id=2666516833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666516833?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:32","pubTimestamp":1789072338,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) just unveiled an announcement. On September 10, 2026, CervoMed announced that initial results from its Phase 2a trial of nefla...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-highlights-late-breaking-neflamapimod-phase-2a-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-highlights-late-breaking-neflamapimod-phase-2a-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666981955","title":"CervoMed Neflamapimod Phase 2a nfvPPA Biomarker Data Set for ISFTD 2026 Oral Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2666981955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666981955?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:54","pubTimestamp":1789041273,"startTime":"0","endTime":"0","summary":"CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral sessionCervoMed set an ISFTD 2026 late-breaking oral session to disclose initial biomarker results from its Phase 2a neflam","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL7WNkBc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2V16.EUR","BCDF","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","LU0314104364.USD","LU2095319765.USD","IE00BQXX3D17.EUR","BK4139","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","NDAQ","BK4588","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","SG9999014013.SGD","LU2210149790.SGD","LU2210150020.SGD","CRVO","IE00BQXX3F31.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666159886","title":"CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Have Been Accepted as a Late-Breaking Oral Session at Isftd 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666159886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666159886?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:30","pubTimestamp":1789039800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA93NTC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666986785","title":"CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666986785","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666986785?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:30","pubTimestamp":1789039800,"startTime":"0","endTime":"0","summary":"12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359388/0/en/cervomed-announces-initial-results-from-the-phase-2a-clinical-trial-of-neflamapimod-in-nonfluent-variant-primary-progressive-aphasia-nfvppa-have-been-accepted-as-a-late-breaking-or.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","DLB","IE0004445015.USD","PGR","BK4097","IE00BFSS7M15.SGD","LU0353189680.USD","SG9999003800.SGD","LU1430594728.SGD","LU0731783394.SGD","LU1035773651.USD","LU0742537680.HKD","SG9999004303.SGD","LU0240877869.USD","LU0354030438.USD","LU0348723411.USD","LU0289960550.SGD","LU0052756011.USD","LU1267930227.SGD","LU0240878834.USD","LU0205194284.USD","BK4585","LU0345774631.USD","LU1481011911.USD","LU1366192091.USD","LU0070302665.USD","BK4588","LU2355687059.USD","IE00BN29S564.USD","CRVO","LU0175139822.USD","IAK","BK4139","LU0170899867.USD","IE00BJJMRY28.SGD","IE00B775H168.HKD","LU0205193047.USD","LU0772969993.USD","LU1983260115.SGD","LU0731783048.USD","IE00BZ1G4Q59.USD","LU1481011671.HKD","LU1069347547.HKD","IE00BJJMRX11.SGD","KBWP","LU1599440770.SGD","IE0005OL40V9.USD","LU1509826696.USD","IE00B7KXQ091.USD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378128","title":"CervoMed to Participate in September Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378128","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378128?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:30","pubTimestamp":1788867000,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (\"CervoMed\" or the \"Company\"), to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357522/0/en/cervomed-to-participate-in-september-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660285466","title":"CervoMed price target lowered to $7 from $9 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2660285466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660285466?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:40","pubTimestamp":1787222411,"startTime":"0","endTime":"0","summary":"Roth Capital lowered the firm’s price target on CervoMed (CRVO) to $7 from $9 and keeps a Buy rating on the shares. The firm updated the company’s ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-7-from-9-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-7-from-9-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974921","title":"CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974921?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:35","pubTimestamp":1786534500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197967","title":"CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197967","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658197967?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:36","pubTimestamp":1786530976,"startTime":"0","endTime":"0","summary":"Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on CervoMed and keeping the price target at $25.00. Ram Selvaraju has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomed-buy-rating-reiterated-as-dementia-pipeline-advances-25-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomed-buy-rating-reiterated-as-dementia-pipeline-advances-25-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936286","title":"CervoMed is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936286","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936286?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:23","pubTimestamp":1786364580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658443933","title":"CervoMed Q2 Net Loss Lower than Estimates as Costs Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2658443933","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658443933?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:38","pubTimestamp":1786361915,"startTime":"0","endTime":"0","summary":"CervoMed Q2 net loss lower than estimates as costs dropOverviewUS biotech developer's Q2 net loss was lower than analyst expectationsCompany completed $20.5 mln equity financings, extending cash runwa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4007","PTH","BK4585","BK4139","BK4505","AXSM","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933970","title":"CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933970","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933970?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:33","pubTimestamp":1786361613,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61070579/cervomed-q2-eps-0-64-misses-0-60-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933484","title":"Press Release: CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658933484?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:30","pubTimestamp":1786361400,"startTime":"0","endTime":"0","summary":"partnership to advance its neflamapimod program into a Phase 3 clinical. -- CervoMed received a notice of allowance from the U.S. Patent and. Trademark Office in June 2026 for a new patent covering the use of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","LU0345774391.USD","LU0205194284.USD","LU0205193047.USD","LU0348723411.USD","LU0240878834.USD","AAIC","CRVO","BK4139","DLB","BK4132","LU0345774631.USD","BK4097","BK4110","LU0240877869.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621505","title":"CervoMed Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621505","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621505?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:01","pubTimestamp":1786140102,"startTime":"0","endTime":"0","summary":"CervoMed Inc reports results for the quarter ended June 30 - Earnings SummaryCervoMed IncCRVO.OQreported a quarterly adjusted loss of 64 cents per share for the quarter ended June 30, higher than the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626905","title":"Cervomed Q2 FY26 Net Loss Widens 5% to $6.57 Million; Revenue Turns to None","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626905","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626905?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:28","pubTimestamp":1786134486,"startTime":"0","endTime":"0","summary":"Cervomed Q2 FY26 net loss widens 5% to $6.57 million; revenue turns to noneCervomed posted a net loss of $6.57 million in Q2, widening 5% from the prior-year quarter.Operating loss was $6.68 million, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL1JMhz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542295","title":"CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542295","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657542295?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929400,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  05, 2026  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339214/0/en/CervoMed-to-Participate-in-Fireside-Chat-to-Highlight-Recent-Progress-in-the-Neflamapimod-Clinical-Development-Program-at-the-Canaccord-Genuity-46th-Annual-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","CRVO","PRGS","BK4139","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656551361","title":"CervoMed Inc Expected to Post a Loss of 87 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656551361","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656551361?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:23","pubTimestamp":1785849786,"startTime":"0","endTime":"0","summary":"CervoMed Inc <CRVO.OQ> expected to post a loss of87cents a share - Earnings PreviewCervoMed IncCRVO.OQCRVO.Ois expected to  show a fall in quarterly revenue when it reports  results on August 6 (estim","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411P7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555079","title":"CervoMed’s neflamapimod gains UK Innovation Passport","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555079?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:19","pubTimestamp":1785845960,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has provided an announcement. On August 4, 2026, CervoMed announced that neflamapimod, its oral small-molecule drug targeting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomeds-neflamapimod-gains-uk-innovation-passport?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomeds-neflamapimod-gains-uk-innovation-passport?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553429","title":"CervoMed Says UK Grants ILAP Innovation Passport for Neflamapimod in Lewy Body Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553429","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553429?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:52","pubTimestamp":1785844374,"startTime":"0","endTime":"0","summary":"CervoMed says UK grants ILAP Innovation Passport for neflamapimod in Lewy body dementiaCervoMed’s neflamapimod received an Innovation Passport under the UK Innovative Licensing and Access Pathway for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLWFK2r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656115539","title":"CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (Ilap) for Treatment of Dementia with Lewy Bodies (Dlb)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656115539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656115539?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:15","pubTimestamp":1785834900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA7XJGMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0491},{"period":"3month","weight":-0.2779},{"period":"6month","weight":-0.3226},{"period":"1year","weight":-0.6893},{"period":"ytd","weight":-0.681}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.2099},{"period":"1year","weight":0.1605},{"period":"ytd","weight":0.125}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.023389},{"month":2,"riseRate":0.5,"avgChangeRate":0.085839},{"month":3,"riseRate":0.5,"avgChangeRate":0.326048},{"month":4,"riseRate":0.3,"avgChangeRate":-0.063988},{"month":5,"riseRate":0.4,"avgChangeRate":0.116259},{"month":6,"riseRate":0.1,"avgChangeRate":-0.109707},{"month":7,"riseRate":0.2,"avgChangeRate":-0.086929},{"month":8,"riseRate":0.7,"avgChangeRate":0.070615},{"month":9,"riseRate":0.1,"avgChangeRate":-0.110115},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.039339},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.045938},{"month":12,"riseRate":0.3,"avgChangeRate":-0.206034}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}